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Introduction
Elevated lead exposure in early life is 
 associated with growth retardation, neuro-
toxicity, impaired cognitive development in 
infancy, and deficits in attention and execu-
tive function (Bellinger et al. 1986, 1987). 
Accumulating evidence also indicates that the 
effect of lead exposure in early childhood can 
change neurochemistry (Binns et al. 2007), 
cause neurobehavioral and cognitive deficits 
in later life (Finkelstein et al. 1998; Sanders 
et al. 2009; Winneke et al. 1983; Zahran 
et al. 2009), decrease brain volume, and 
increase the rate of criminal arrest in adult-
hood (Cecil et al. 2008; Wright et al. 2008). 
Although the current actionable concentra-
tion for lead is 5 μg/dL in the United States, 
the threshold for its toxicity is unknown. 
Furthermore, the mechanisms by which lead 
exposure affects diverse neuropathological 
outcomes is not clearly defined, although 
epigenetic mechanisms have been proposed 
(Wright et al. 2010).
Environmental exposures to both physical 
and chemical agents, especially during early 
development, can induce alterations in 
DNA methylation that alter disease suscep-
tibility in adulthood (Bernal et al. 2013; 
Dolinoy et al. 2006, 2007; Waterland and 
Jirtle 2003). Animal studies likewise suggest 
that epigenetic modifications may link lead 
exposure to neurotoxicity and attention 
deficit disorders (Faulk et al. 2013; Luo 
et al. 2014), but stable epigenetic targets 
responsive to early lead exposure in humans 
remain uncharacterized.
Because of the relative ease of measuring 
genomic DNA cytosine methylation at CpG 
dinucleotides, this end point is the most 
commonly investigated epigenetic modifi-
cation in epidemiologic studies. In vitro 
and in vivo studies demonstrate that DNA 
methyla tion is altered by exposure to toxic 
metals, including arsenic, cadmium, and 
lead (Bolin et al. 2006; Reichard et al. 2007; 
Takiguchi et al. 2003). The only epigenetic 
studies conducted in humans thus far have 
evaluated DNA methylation at Alu and LINE 
repeat elements. They showed associations 
between maternal patella lead levels and 
global DNA hypomethylation in newborns 
(Pilsner et al. 2009) and adult males (Wright 
et al. 2010). Although the biological signifi-
cance of reduced DNA methylation at 
repetitive elements in lead-exposed humans is 
unknown, this epigenetic change also occurs 
frequently in cancer, where it is believed 
to result in chromosomal instability and 
genomic mutations (Wilson et al. 2007).
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Background: Lead exposure during early development causes neurodevelopmental disorders by 
unknown mechanisms. Epidemiologic studies have focused recently on determining associations 
between lead exposure and global DNA methylation; however, such approaches preclude the 
 identification of loci that may alter human disease risk.
oBjectives: The objective of this study was to determine whether maternal, postnatal, and early 
childhood lead exposure can alter the differentially methylated regions (DMRs) that control the 
monoallelic expression of imprinted genes involved in metabolism, growth, and development.
Methods: Questionnaire data and serial blood lead levels were obtained from 105 participants 
(64 females, 41 males) of the Cincinnati Lead Study from birth to 78 months. When participants 
were adults, we used Sequenom EpiTYPER assays to test peripheral blood DNA to quantify CpG 
methylation in peripheral blood leukocytes at DMRs of 22 human imprinted genes. Statistical 
analyses were conducted using linear regression.
results: Mean blood lead concentration from birth to 78 months was associated with a signifi-
cant decrease in PEG3 DMR methylation (β = –0.0014; 95% CI: –0.0023, –0.0005, p = 0.002), 
stronger in males (β = –0.0024; 95% CI: –0.0038, –0.0009, p = 0.003) than in females (β = –0.0009; 
95% CI: –0.0020, 0.0003, p = 0.1). Elevated mean childhood blood lead concentration was also asso-
ciated with a significant decrease in IGF2/H19 (β = –0.0013; 95% CI: –0.0023, –0.0003, p = 0.01) 
DMR methylation, but primarily in females, (β = –0.0017; 95% CI: –0.0029, –0.0006, p = 0.005) 
rather than in males, (β = –0.0004; 95% CI: –0.0023, 0.0015, p = 0.7). Elevated blood lead concen-
tration during the neonatal period was associated with higher PLAGL1/HYMAI DMR methylation 
regardless of sex (β = 0.0075; 95% CI: 0.0018, 0.0132, p = 0.01). The magnitude of associations 
between cumulative lead exposure and CpG methylation remained unaltered from 30 to 78 months.
conclusions: Our findings provide evidence that early childhood lead exposure results in sex-
dependent and gene-specific DNA methylation differences in the DMRs of PEG3, IGF2/H19, and 
PLAGL1/HYMAI in adulthood.
citation: Li Y, Xie C, Murphy SK, Skaar D, Nye M, Vidal AC, Cecil KM, Dietrich KN, Puga A, 
Jirtle RL, Hoyo C. 2016. Lead exposure during early human development and DNA methyla-
tion of imprinted gene regulatory elements in adulthood. Environ Health Perspect 124:666–673; 
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Imprinted genes are characterized by 
parent-of-origin–dependent monoallelic 
expression, with the functionally haploid 
state controlled by differentially methyl-
ated regions (DMRs). The inherited imprint 
methylation marks at these DMRs are estab-
lished during gametogenesis (i.e., gametic 
imprints) or early in embryogenesis (i.e., 
somatic imprints) (Barlow 2011; Reik and 
Walter 2001). Epigenetic dysregulation of 
imprinted genes is associated with diseases, 
including cancer, diabetes, obesity, and devel-
opmental and neurological disorders (Ishida 
and Moore 2013; Murphy and Jirtle 2003). 
DNA methylation marks at imprinted DMRs 
are generally maintained in tissues from the 
three germ layers (Murphy et al. 2012b; 
Waterland et al. 2010; Woodfine et al. 2011). 
Furthermore, with imprinted genes often 
occurring in clusters (Edwards et al. 2007) 
and with the potential for network regulation 
(Varrault et al. 2006), the methylation status 
of a single DMR could affect the expression of 
multiple genes.
The availability of childhood blood lead 
concentration data and adult peripheral blood 
DNA from the Cincinnati Lead Study cohort 
(Cecil et al. 2008; Dietrich et al. 1987, 1993, 
2001) provided the impetus for the first 
determination of prenatal and postnatal lead 
exposure associations with DNA methylation 
in adulthood for the DMRs of 22 imprinted 
genes, as recently described (Skaar et al. 2012).
Materials and Methods
Study population. Participants comprised 41 
men and 64 women born between 1979 and 
1984 who were enrolled in the Cincinnati 
Lead Study and were successfully recontacted 
in 2008–2010. Accrual and lead measure-
ment methods have been described in detail 
(Cecil et al. 2008; Dietrich et al. 1987). 
Briefly, pregnant women living in neigh-
borhoods with high prevalence of pediatric 
lead poisoning were eligible. Women with 
type 1 or type 2 diabetes and neurological, 
psychiatric, or drug addiction disorders were 
excluded, as were offspring with defects or 
birth weight < 1,500 g. Using anodic strip-
ping voltammetry (Roda et al. 1988), lead 
concentrations were measured in first- and 
second-trimester maternal peripheral blood 
and in blood collected from their children 
at 10 days of age, every 3 months for the 
first 60 months, and every 6 months from 
60 to 78 months. Umbilical cord blood was 
not measured due to clotting. During preg-
nancy, questionnaires were used to collect 
data on maternal race/ethnicity (black/
white), the number of cigarettes smoked per 
day, education, occupation, continuous IQ, 
use of alcohol (yes/no), marijuana (yes/no), 
and narcotics (yes/no), and children’s IQ at 
age 6.5 years. The protocol was approved 
by review boards for Cincinnati, Duke, and 
North Carolina State Universities.
Specimen handling. During the 2008 
visit, 108 participants with an average age of 
27 years (25–30 years) provided informed 
consent before peripheral blood specimens for 
DNA methylation analysis were collected; 105 
also had covariable data. Blood was collected 
in K2EDTA-treated vaccutainer tubes, centri-
fuged for plasma and buffy coat isolation, 
and shipped to the Jirtle laboratory at Duke 
University for DNA methylation analysis.
Quantitative methylation analysis. 
DNA was extracted using Puregene reagents 
according to manufacturer’s protocol (Qiagen, 
Valencia, CA). In the Supplemental Material, 
Table S1 summarizes DMR amplicon cleavage 
fragments, including CpG content and posi-
tions. DNA amplification used a touchdown 
polymerase chain reaction (PCR) protocol.
Quantitative DNA methylation analysis 
was performed in two batches using the 
Sequenom Mas sARRAY Ep iTYPER 
(Sequenom, San Diego, CA). Primers for 
human imprinted genes were designed with 
the use of Epidesigner software (Sequenom) 
to amplify approximately 400–600 bp of the 
imprinted gene DMRs. Cycling conditions 
for touchdown PCR used are in Supplemental 
Material, Table S2, and primers and amplicon 
data are provided in Supplemental Material, 
Table S3. Genomic DNA (2 μg) was treated 
with sodium bisulfite using the EpiTect 
kit, according to manufacturer’s protocols 
(Qiagen, Valencia, CA). Bisulfite-converted 
DNA (50 ng) was amplified by PCR using 
HotStarTaq (Qiagen).
PCR products were processed by dephos-
phorylation of unincorporated dNTPs. They 
were then transcribed in vitro with concur-
rent RNase cleavage using T-cleavage assays 
according to the manufacturer’s standard 
protocol (Sequenom). The transcrip-
tion reaction was conditioned to remove 
cations by adding 20 μL H2O and 6 mg of 
Clean Resin (Sequenom). Subsequently, the 
samples were spotted on a 384-pad Spectro-
CHIP (Sequenom), using a MassARRAY 
Nanodispenser (Samsung, Irvine, CA), 
followed by spectral acquisition on a 
MassARRAY analyzer compact MALDI-TOF 
MS (matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometer) (Sequenom). 
The percent methylation of CpG sites for 
each cleavage fragment was determined using 
EpiTyper software (Sequenom).
The Sequenom MassARRAY measured 
DNA methylation using fragments of reverse-
transcribed PCR products, and data output 
is in CpG “units” in which multiple CpG 
sites may reside within a single fragment 
produced by RNase cleavage of transcripts of 
DMR amplicons (see Supplemental Material, 
Table S1). The mass difference between 
fragments with “T” and “C” bases (bisulfite-
converted unmethylated, and unconverted 
methylated cytosines, respectively) at CpG 
sites was detected, and the ratio of alter-
nate masses was quantitated to generate the 
methyla tion fraction. For fragments with 
multiple CpGs, the methylation value was 
calculated as an average of all sites. Visual 
inspection of the output from the mass spec-
trometer for such fragments with multiple 
CpGs provided an estimate of the accuracy of 
this average for individual sites. The detection 
of primarily two peaks representing hypo-
methylated and hypermethylated fragments 
was indicative of strand-specific, cis-regulated 
differential methylation, and the methylation 
value for the entire fragment was considered 
to represent each individual CpG site. For 
most fragments with multiple CpG sites, this 
two-peak output was the case.
In the Supplemental Material, Table S1 
summarizes fragments for each amplicon, CpG 
content, and position within the fragments and 
shows which fragments were excluded from 
analysis due to low or high mass outside the 
detection range, fragment duplication, overlap, 
or success rate below the 95% threshold. 
Methylation values for fragments with multiple 
CpG sites were weighted when included in 
DMR average methylation, and fragments 
with duplicate masses were included separately, 
such that the DMR average methylation is the 
same as if data for each CpG were available.
R e p r o d u c i b i l i t y  o f  5 – 1 0 %  f o r 
MassARRAY methylation analysis was verified 
in triplicate for the 22 DMRs using control 
conceptus tissues representing the three germ 
layers. In these control fetal tissues, the mean 
DNA methylation ranged from 45% to 60%. 
In humans exposed to varying lead levels, 
the mean DNA methylation ranged from 
37% to 74% (see Supplemental Material, 
Table S3). When > 5% of samples produced 
no signals, indicating errors in spotting or 
failures in amplification or cleavage, the run 
was discarded.
Statistical analyses, DNA methylation, 
and covariable data .  A total  of 172 
CpG-containing cleavage fragments from 
22 genomically imprinted gene DMRs had 
methylation percentages available for the 105 
participants. The number of analyzed regions 
for each DMR and the mean methylation 
for each DMR computed from nonmissing 
CpG-containing fragments are in the last two 
columns of Supplemental Material, Table S3. 
The R-package was used for data analysis (R 
Core Team 2013).
Lead concentrations (micrograms per 
deciliter) were analyzed as age-specific 
concentrations cumulatively defined as 
the sum of blood lead measurements up 
to and including the value measured at that 
age, divided by the number summed (e.g., 
Li et al.
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concentrations at 10 days + 3 months 
+ 6 months/3 = average cumulative 
concentrations at age 6 months). Lead values 
were also arrayed and the maximum lead value 
for each participant was identified. Lead was 
also categorized into four developmental stages 
at measurement: prenatal (first- or second-
trimester gestation); neonatal (age 10 days); 
early childhood, coinciding with higher 
concentrations characteristic of the crawling/
oral exploratory developmental window 
(age 3–30 months); and middle childhood, 
coinciding with declining concentrations 
(age 33–78 months). Factors shown to be 
associated with lead concentrations, from 
previous analyses of these data (Cecil et al. 
2008; Dietrich et al. 1987), and factors known 
to be associated with DNA methylation were 
evaluated for confounding in the overall mean 
and maximum saturated models. Only those 
with a p-value < 0.05 were retained in refined 
models. Factors evaluated for confounding 
were maternal education, smoking, and race, 
as well as offspring sex and batch. Only sex 
(male/female), batch (first or second), and 
smoking (none, ≤ 0.5, 1, 1.5, and 2 packs per 
day, computed from the number of cigarettes 
smoked daily, assuming 20 cigarettes in a pack) 
remained significant, and were retained in 
refined models.
Because some DNA methylation values 
were not normally distributed, the log2 of the 
standardized regression coefficients, 
= log ,1M values BetaValue
BetaValue- 2 -a k: D
were used in adjusted linear regression models. 
These were compared with unstandardized 
regression coefficients, and the results were 
similar (data not shown). For ease of interpre-
tation, we present unstandardized regression 
coefficients with 95% confidence intervals 
(CIs) in tables, whereas regression coefficients 
at each lead measurement are plotted without 
confidence intervals. A p-value ≤ 0.05 was 
considered statistically significant.
The limited sample size precluded adjust-
ment for multiple comparisons. Instead, 
we included only DMRs for which the 
level of methylation of more than three 
CpG-containing fragments were correlated 
r > 0.8, suggesting cis-acting regulation (data 
not shown). The CpG-containing frag-
ments also had to have persistent significant 
(p < 0.05) associations with lead exposure for 
any four consecutive mean lead measurements 
(e.g., associations were significant and in the 
same direction for lead levels measured at 3, 6, 
9, and 12 months) as seen in Figure 1.
Results
Study participants, lead concentrations, 
and DNA methylation .  The majority 
(90%) of participants were born to black 
women, ~ 70% had less than a high school 
education, and the median IQ was 75 
(Table 1). Although ~ 50% of participants 
were exposed to cigarette smoke in utero, 
exposure to alcohol,  mari juana,  and 
narcotics was uncommon (< 13%). Prenatal 
mean (± SD) blood lead concentration 
was 9.1 ± 6.0 μg/dL, postnatal mean lead 
concentration was 13.6 ± 5.5 μg/dL, and the 
maximum mean was 25.3 ± 5.3 μg/dL. Blood 
lead concentrations in males and females 
were comparable throughout the study visits; 
Table 1. Characteristics of study participants [n (%)].
Characteristic Total sample Males (n = 41) Females (n = 64)
Race
White 10 (9.5) 5 (12.2) 5 (7.8)
Black 95 (90.5) 36 (87.8) 59 (92.2)
Education
≤ High school 71 (67.7) 33 (80.5) 38 (59.3)
> High school 34 (32.4) 8 (19.5) 26 (40.6)
Range (years) 6–16 9–16 6–16
Maternal alcohol use
Yes 13 (12.4) 4 (9.8) 9 (14.1)
No 92 (87.6) 37 (90.2) 55 (85.9)
Maternal narcotic use
Yes 1 (1.5) 0 (0.0) 1 (1.6)
No 104 (98.5) 40 (100.0) 63 (98.4)
Maternal marijuana use
Yes 11 (10.5) 4 (9.8) 7 (10.9)
No 94 (89.5) 37 (90.2) 57 (89.1)
Maternal tobacco use during pregnancya
None 48 (45.7) 23 (56.1) 25 (39.1)
< pack/day 43 (41.0) 13 (31.7) 30 (40.6)
1 pack/day 11 (10.5) 3 (7.2) 8 (12.5)
1.5 packs/day 2 (1.9) 1 (2.4) 1 (1.6)
2 packs/day 1 (1.0) 1 (2.4) 0 (0)
Birth weight (g) [median (range)] 3,096 (1,990–4,340) 3,184 (2,000–4,260) 3,040 (1,990–4,340)
Maternal IQ [median (range)] 75 (58–102) 74 (61–97) 76 (58–102)
Participant IQ [median (range)] 87 (50–116) 87 (50–111) 88 (67–116)
Lead concentrations during developmental windows (μg/L)
Childhood (birth to 78 months) (mean) 13.6 (5.5) 13.7 (5.5) 13.5 (5.5)
Neonatal period (≤ 28 days) 14.5 (5.9) 14.5 (6.1) 14.5 (5.7)
Early childhood (age ≤ 30 months) 14.5 (5.9) 14.5 (6.1) 14.5 (5.7)
Middle childhood (> 30–78 months) 13.0 (6.1) 13.2 (5.9) 12.8 (6.2)
Age (years) at blood draw for DNA methylation 
determination [median (range)]
26.7 (25.4–29.6) 26.9 (25.5–29.6) 26.5 (25.4–28.4)
aPacks per day is based on a typical American package of 20 cigarettes.
Figure 1. Number of consecutive ages of measurement with significant (p ≤ 0.05) association of DMR 
methylation with lead exposure from birth to age 78 months. The dashed line indicates the threshold for 
imprinted gene inclusion. 
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the concentration increased rapidly with 
age, peaking at age 20–25 months, and then 
decreased (Figure 2). Lead concentrations 
and the distribution of covariable data were 
comparable with those who were successfully 
contacted again in 2008–2010 (p ≥ 0.14).
Data for 37 of 172 CpG-containing 
fragments were missing for > 5% of partici-
pants, leaving 135 fragments for analysis. The 
mean DMR methylation levels for the 105 
participants exposed to varying levels of lead 
ranged from 37% to 74% (see Supplemental 
Material, Table S3).
Associations between early lead exposure 
and DMR methylation. Lead concentra-
tions were highly correlated within indi-
viduals, especially in early childhood (see 
Supplemental Material, Table S4). Of the 
22 DMRs, those for six imprinted genes 
had more than three CpGs with correla-
tion > 0.8—PEG10, DLK1/MEG3, DIRAS, 
PEG3, IGF2/H19, and PLAGL1/HYMA1. 
However, the mean and maximum lead 
concentrations were persistently associated 
only with the DNA methylation of DMRs 
for PEG3, IGF2/H19, and PLAGL1/HYMAI 
(Table 2 and Figure 3; see also Supplemental 
Material, Table S5).
Childhood lead leve l s  and PEG3 
DMR methylation. Table 2 shows an asso-
ciation between mean lead concentrations 
across childhood and lower PEG3 DMR 
methylation in adulthood (β = –0.0014; 
95% CI: –0.0023, –0.0005, p = 0.002). 
These associations were primarily in males 
(β = –0.0024; 95% CI: –0.0038, –0.0009, 
p  = 0 .003)  compared  wi th  f emale s 
(β = –0.0009; 95% CI: –0.0020, 0.0003, 
p = 0.1). The cross-product term p-value for 
mean lead concentrations and sex was 0.09. 
This association in males corresponds to a 
0.24% decrease in CpG methylation at the 
PEG3 DMR, for every 1-μg/dL increase in 
lead concentration.
There were statistically significant 
inver se  a s soc ia t ions  be tween  PEG3 
DMR methyla tion and lead levels in early 
(β = –0.0012; 95% CI: –0.0020, –0.0004, 
p  =  0 .005)  and  midd l e  ch i ldhood 
(β = –0.0013; 95% CI: –0.0021, –0.0005, 
p  = 0 .002) .  The  a s soc i a t ions  were 
significant only in males during early 
(β = –0.0023; 95% CI: –0.0036, –0.0009, 
p = 0.002 for males and β = –0.0006; 
95% CI:  –0.0016,  0.0005,  p = 0.3 
for  f emale s )  and middle  ch i ldhood 
(β = –0.0018; 95% CI: –0.0031, –0.0004, 
p = 0.02 for males and β = –0.0009; 
95% CI: –0.0020, 0.0001, p = 0.1 for 
females). Cross-product terms for early and 
middle childhood lead exposure and sex were 
p = 0.04 and 0.3, respectively. There were no 
statistically significant associations between 
prenatal or neonatal lead concentration and 
PEG3 DMR methylation, although the direc-
tion of associations was largely similar to 
those of early and middle childhood.
Figure 2. Mean postnatal circulating lead concentrations in males (blue circles, dashed line) and females 
(black circles, solid line) versus childhood age. Darker gray area indicates early childhood—10 days to 
30 months; lighter gray area indicates middle childhood—30 to 78 months.)
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Table 2. Regression coefficients for the association between mean lead exposure and PEG3, IGF2/H19, and PLAGL1/HYMAI DMR methylation.a,b
DMR/CpG 
Lead exposure
Both sexes Males Females
β (95% CI), p-value β (95% CI), p-value β (95% CI), p-value
PEG3
Mean life childhood lead levels (birth to age 78 months) –0.0014 (–0.0023, –0.0005), 0.002 –0.0024 (–0.0038, –0.0009), 0.003 –0.0009 (–0.0020, 0.0003), 0.1
Prenatal lead levels (2nd or 3rd trimester) –0.0011 (–0.0028, 0.0005), 0.2 0.00001 (–0.0028, 0.0028), 1.0 –0.0017 (–0.0037, 0.0004), 0.1
Neonatal lead levels (age 10 days) –0.0010 (–0.0025, 0.0004), 0.2 –0.0011 (–0.0030, 0.0007), 0.2 –0.0010 (–0.0035, 0.0016), 0.5
Early childhood levels (age 3–30 months) –0.0012 (–0.0020, –0.0004), 0.005 –0.0023 (–0.0036, –0.0009), 0.002 –0.0006 (–0.0016, 0.0005), 0.3
Middle childhood levels (age 33–78 months) –0.0013 (–0.0021, –0.0005), 0.002 –0.0018 (–0.0031, –0.0004), 0.02 –0.0009 (–0.0020, 0.0001), 0.1
IGF2/H19
Mean life childhood lead levels (birth to age 78 months) –0.0013 (–0.0023, –0.0003), 0.01 –0.0004 (–0.0023, 0.0015), 0.7 –0.0017 (–0.0029, –0.0006), 0.005
Prenatal lead levels (2nd or 3rd trimester) –0.0004 (–0.0022, 0.0014), 0.7 0.0007 (–0.0025, 0.0040), 0.7 –0.0011 (–0.0033, 0.0011), 0.3
Neonatal lead levels (age 10 days) –0.0013 (–0.0029, 0.0003), 0.1 –0.0009 (–0.0032, 0.0013), 0.4 –0.0025 (–0.0052, 0.0002), 0.08
Early childhood levels (age 3–30 months) –0.0009 (–0.0019, 0.00001), 0.06 0.0004 (–0.0014, 0.0022), 0.7 –0.0016 (–0.0027, –0.0005), 0.007
Middle childhood levels (age 33–78 months) –0.0013 (–0.0022, –0.0004), 0.005 –0.0009 (–0.0026, 0.0008), 0.3 –0. 0016 (–0.0027, –0.0004), 0.008
PLAGL1/HYMAI
Mean life childhood lead levels (birth to age 78 months) 0.0016 (–0.0021, 0.0052), 0.4 0.0023 (–0.0046, 0.0091), 0.5 –0.0001 (–0.0045, 0.0044), 1.0
Prenatal lead levels (2nd or 3rd trimester) –0.0023 (–0.0091, 0.0044), 0.5 –0. 0041 (–0.0160, 0.0078), 0.5 –0.0023 (–0.0104, 0.0058), 0.6
Neonatal lead levels (age 10 days) 0.0075 (0.0018, 0.0132), 0.01 0.0074 (–0.0001, 0.0150), 0.06 0.0030 (–0.0069, 0.0129), 0.6
Early childhood levels (age 3–30 months) 0.0024 (–0.0011, 0.0059), 0.2 0.0055 (–0.0006, 0.0115), 0.08 0.00001 (–0.0042, 0.0042), 1.0
Middle childhood levels (age 33–78 months) 0.0006 (–0.0028, 0.0040), 0.7 –0.0009 (–0.0071, 0.0053), 0.8 –0.0001 (–0.0043, 0.0042), 1.0
aUnstandardized regression coefficients. All models were adjusted for batch (first or second) and maternal cigarette smoking (none, one-half, 1 and 2 packs a day). Models of 
combined estimates for males and females are also adjusted for sex. bMean for each developmental period (early childhood) was derived by summing up lead levels for the participant 
and dividing by the number of observations.
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Patterns of association observed in 
overall and sex-specific mean lead concen-
trations were also evident when maximum 
lead concentrations were considered (see 
Supplemental Material, Table S5). The 
association between the maximum lead 
concentration and decreased PEG3 DMR 
methylation in adulthood (β = –0.0007; 
95% CI: –0.0012, –0.0003, p = 0.003) was 
also more apparent in males (β = –0.0013; 
95% CI: –0.0021, –0.0006, p-value = 0.001) 
than in females (β = –0.0004; 95% CI: 
–0.0010, 0.0002, p = 0.3). Maximum lead 
concentrations in the prenatal and neonatal 
ages were too low for meaningful analyses.
To refine potential windows of vulner-
ability, nonstandardized regression coefficients 
were plotted for the associations between DMR 
methylation and averaged cumulative lead 
concentrations for each age at which lead was 
measured (Figure 3). Figure 3A confirms the 
association in Table 2 that higher lead exposure 
is associated with lower PEG3 DMR methyla-
tion, and also shows that this association does 
not vary significantly after age 12–20 months 
to age 6.5 years, despite wide variation in lead 
concentrations during the observation period. 
These associations are male-specific.
Childhood lead levels and IGF2/H19 
DMR methylation. Regression coefficients 
and p-values for the association between mean 
lead concentration and IGF2/H19 DMR 
methylation in adulthood are also shown in 
Table 2. Mean childhood lead concentra-
tion was significantly associated with adult 
IGF2/H19 DMR methylation (β = –0.0013; 
95% CI: –0.0023, –0.0003, p = 0.01). 
This association may be stronger in females 
(β = –0.0017; 95% CI: –0.0029, –0.0006, 
p = 0.005) than in males (β = –0.0004; 
95% CI: –0.0023, 0.0015, p = 0.7).
Associations for lead exposure and 
IGF2 /H19  DMR methy l a t ion  were 
a l so  found in  ea r ly  (β  =  –0 .0016; 
95% CI: –0.0027, –0.0005, p = 0.007) 
and middle childhood (β = –0.0016; 
95% CI: –0.0027, –0.0004, p = 0.008) in 
females. These associations were weaker 
and less consistent in males, for early 
(β = 0.0004; 95% CI: –0.0014, 0.0022, 
p = 0.7) and middle childhood (β = –0.0009; 
95% CI: –0.0026, 0.0008, p = 0.3). The 
p-values for cross-product terms for early and 
middle childhood lead levels and sex were 
0.10 and 0.6, respectively. This age- and 
sex-specific pattern of association was also 
noted when maximum blood lead concen-
trations were evaluated (see Supplemental 
Material, Table S5). As with the PEG3 DMR 
methylation, associations with prenatal and 
neonatal exposure were weaker although in 
the same direction.
Further exploration of cumulative lead 
concentrations suggests a female-specific 
association between lead exposure and 
lower methylation at the IGF2/H19 DMR. 
The magnitude of the association between 
cumulative lead concentration and IGF2/H19 
DMR methylation was the same after 
12–20 months (Figure 3B). As with PEG3 
DMR, this similarity persists for the entire 
observation period.
Childhood lead levels and PLAGL1/
HYMAI  DMR methy la t ion .  Unl ike 
IGF2/H19  and PEG3 ,  which showed 
no evidence for associat ion between 
neonatal lead exposure and DMR methyla-
tion, PLAGL1/HYMAI DMR methyla-
tion was positively associated with lead 
levels during this period (β = 0.0075; 
Figure 3. Unstandardized regression coefficients for associations between DMR methylation for PEG3 (A), 
IGF2/H19 (B), and HYMA/PLAGL1 (C) and the average cumulative lead level (obtained by summing up blood 
level measurements, up to and including the value measured at that age, divided by the number summed, 
in males (blue circles) and females (black circles). The darker gray area indicates early childhood; the 
lighter gray area indicates middle childhood. 
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95% CI: 0.0018, 0.0132, p = 0.01). The 
wide confidence intervals suggest that this 
association varied little between males 
(β = 0.0074; 95% CI: –0.0001, 0.0150, 
p = 0.06) and females (β  = 0.0030; 
95% CI: –0.0069, 0.0129, p = 0.6). No 
significant association was found between 
lead exposure and PLAGL1/HYMAI DMR 
methylation at any other age. Refined age-
dependent and sex-specific analyses suggest 
that the magnitude of associations remained 
unaltered after ~ 12–20 months to the end of 
the observation period (Figure 3C).
Discussion
The DMRs regulating monoallelic expression 
of imprinted genes are proposed to function 
as epigenetic archives of early exposure to 
environmental factors (Hoyo et al. 2009). 
Nevertheless, until now, no empirical data 
have demonstrated associations between early 
exposure to lead and adult CpG methylation 
at DMRs controlling the parent-of-origin 
silencing of imprinted genes. Environmentally 
induced DNA methylation changes at imprint 
DMRs are usually stable once established 
(Heijmans et al. 2008), and have been asso-
ciated with common chronic diseases and 
conditions, including neurological disorders, 
obesity, type 2 diabetes, and some cancers 
(Azzi et al. 2013; Feinberg 2007; Hoyo et al. 
2012; Ishida and Moore 2013).
We have undertaken an analysis of 22 
DMRs regulating human imprinted genes, 
and evaluated relationships between DNA 
methylation in adulthood and lead exposure 
spanning from the first or early second 
trimester to age 6.5 years. Our key findings 
were that childhood lead exposure was associ-
ated with significantly lower DNA methyla-
tion levels at the DMR regulating PEG3. 
We also found modest but consistent asso-
ciations between average lead concentration 
and decreased methylation of the IGF2/H19 
DMR, and higher DNA methylation levels 
at the PLAGL1/HYMAI DMR in relation to 
neonatal exposure. These data further indi-
cated that although childhood lead exposure 
was associated with differences in PEG3 DMR 
methylation in males and the IGF2/H19 
DMR methylation in females, the associa-
tion between neonatal lead concentrations and 
PLAGL1/HYMAI DMR methylation may 
not be sex-specific. Notably, lead associations 
with DNA methylation of imprint regulatory 
elements at these three loci were found in lead 
measured before age 30 months, regardless of 
sex or DMR. These data support the conten-
tion that environmentally driven perturbations 
at these DMRs occur early. Furthermore, 
developmental differences between the sexes 
may dictate the patterns of gene regulation 
that ensue in response to early challenges with 
this heavy metal.
PEG3 DMR methylation and early lead 
exposure. Although childhood lead exposure 
has been associated with increased risk of 
neurodevelopmental disorders (Dietrich 
2010), the mechanisms underlying these 
pathological conditions are poorly under-
stood. PEG3 plays a critical role in brain 
development, with expression mainly in 
the mesencephalon and pituitary gland; in 
the adult brain PEG3 is found primarily in 
the hypothalamus and the pituitary gland 
(Li et al. 1999). In mouse models, Peg3 
also plays an important role in social and 
maternal nurturing behaviors, and paternal 
transmission of disrupted Peg3 also leads to 
restricted growth (Chiavegatto et al. 2012; 
Li et al. 1999). In humans, hypermethyl-
ation at this locus has been associated with 
decreased gene expression of this tumor 
suppressor gene in cervical (Nye et al. 2013) 
and ovarian (Feng et al. 2008) cancers. In 
primary neuronal cell cultures derived from 
wild-type, p53-deficient, or Bax-deficient 
mice, overexpression of Peg3 led to decreased 
neuronal viability via p53 and Bax dependent 
pathways (Johnson et al. 2002). It is there-
fore possible that the male-specific reduced 
brain volume recently observed in these study 
participants (Cecil et al. 2008) may result, in 
part, from the dysregulation of PEG3 during 
early development.
Interestingly, early-childhood but not 
prenatal or neonatal lead levels were associated 
with adulthood PEG3 DMR hypomethyl-
ation, an association that may be specific to 
males. Because these DNA methylation marks 
are established early, it is possible that meth-
ylation differences observed were attributable 
to lead accumulated in utero and mobilized 
from soft tissue and bone after birth together 
with concurrent exposure. Alternatively, the 
reduced DNA methylation of the PEG3 
DMR marks may have been established post-
natally (Loke et al. 2013). The latter possi-
bility is consistent with human developmental 
studies suggesting that the first 1,000 days 
can dictate lifetime risk of common diseases 
(Victora et al. 2008). Discriminating between 
these possibilities requires larger studies with 
long-term follow-up.
IGF2/H19 imprinted domain and early 
lead exposure. The paternally expressed insulin-
like growth factor-2 (IGF2) is a commonly 
studied imprinted gene, and is frequently 
shown to be altered epigenetically by in utero 
environmental perturbations, and in cancer 
(Cruz-Correa et al. 2004, 2009; Cui et al. 
2003; Heijmans et al. 2008; Hoyo et al. 2011, 
2012; Murphy et al. 2012a). Dysregulation 
of the IGF2/H19 domain was initially associ-
ated with Beckwith–Wiedemann syndrome 
(BWS) (Engel et al. 2000). Decreased DNA 
methylation at the IGF2/H19 DMR has been 
associated with reduced IGF2 expression in 
bladder cancer (Takai et al. 2001). This occurs 
when enhanced binding of the CTCF insu-
lator protein to the normally unbound paternal 
allele (Nakagawa et al. 2001) blocks promoter 
interactions with downstream enhancers, 
thereby reducing gene expression (Hark 
et al. 2000; Kanduri et al. 2000). Igf2 over-
expression results in animal overgrowth (Sun 
et al. 1997), whereas gene repression results in 
restricted growth (DeChiara et al. 1990). IGF2 
is also required for memory formation (Chen 
et al. 2011).
PLAGL1/HYMA1 imprinted domain 
and early lead exposure. A higher-order regu-
lation of imprinted gene clusters is thought 
to exist and occur through epigenetic marks 
present at imprinting centers (Lewis and 
Reik 2006). Our finding that neonatal lead 
exposure is associated with increased meth-
ylation at the PLAGL1/HYMAI (ZAC) DMR 
regardless of sex is potentially of biological 
importance. In animals, microarray analysis 
shows that knockout of the mouse homolog, 
Zac1 (Plagl1), disrupts a network of coor-
dinately regulated genes containing a large 
number that are also imprinted (Varrault 
et al. 2006). In vitro studies show induction 
of imprinted Igf2, Cdkn1c, H19, Dlk1, and 
Mest when Zac1 is overexpressed (Varrault 
et al. 2006). Conversely, loss of Zac1 expres-
sion in null mice results in inhibition of Igf2, 
Cdkn1c, H19, and Dlk1 expression. Another 
imprinted gene network was identified by 
analyzing chromatin domains in other regions 
of the genome that interact with the Igf2/H19 
domain, in vitro (Zhao et al. 2006). The 
maternally expressed long noncoding H19 
RNA and the methyl-CpG–binding protein 
Mbd1 form a complex that regulates multiple 
imprinted genes by interacting with histone 
lysine methyltransferases. In mice, paternally 
expressed Plagl1 is implicated in transient 
neonatal diabetes when overexpressed (Ma 
et al. 2004). In ovarian cell lines, PLAGL1 
was found to regulate CDKN1C (p57KIP2) 
expression and cell growth by inducing LIT1 
transcription in a methylation-dependent 
manner (Arima et al. 2005). Overexpression 
of PLAGL1  induced IGF2, H19 ,  and 
CDKN1C expression in a prostate cancer cell 
line (Ribarska et al. 2014). Together, these 
studies support a set of imprinted genes func-
tioning in a network, coordinated in part by 
Zac (Finkielstain et al. 2009; Lui et al. 2008). 
Thus, environmentally induced epigenetic 
shifts of the PLAGL1/HYMAI regulatory 
DMR have the potential to alter network-wide 
imprinted gene expression. Studies with a 
larger number of DMRs are required to clarify 
the role of the PLAGL1/HYMAI DMR in the 
higher-order regulation of imprint clusters. 
Nevertheless, our findings are consistent with 
the idea that the far-reaching effects of early 
lead exposure may be mediated by stable, 
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mitotically heritable epigenetic alterations in 
DMRs controlling imprinted gene expression.
A cautious interpretation of our findings 
is warranted. Although lead is known to 
target multiple organs, DNA methylation 
was measured using unfractionated periph-
eral blood collected in adulthood—the only 
accessible cell type—raising concerns about 
potential confounding by cell type, and 
other exposures during the life course that 
could not be evaluated. Another limitation 
of this study is the relatively small sample 
size, which reduced the precision of associa-
tions found. Assay limitations also precluded 
the measurement of DNA methylation for 
~ 50% of CpGs within CpG-containing 
fragments. Because methylation values for 
CpG-containing fragments were averaged 
from individual CpG sites with similar 
methylation values and are cis-acting, such 
missing data should not alter our findings. The 
small amount of peripheral blood leukocyte 
DNA available for methylation analysis also 
precluded the determination of altered gene 
expression via other epigenetic mechanisms 
(e.g., histone modifications and chromatin 
structure changes); however, similar meth-
ylation changes at both the IGF2/H19 and 
PEG3 DMRs have been associated previously 
with altered gene expression in human cancers 
(Cui et al. 2003; Nye et al. 2013). Thus, our 
findings add preliminary support to accu-
mulating evidence indicating that early lead 
exposure and gene-specific, epigenetic dysreg-
ulation of some imprinted gene DMRs may 
contribute to developmental  abnormalities 
(Ishida and Moore 2013).
Our study also has major strengths. They 
include the determination of lead levels 
~ 30 years before quantification of DNA 
methylation levels at imprinted gene DMRs. 
The numerous measurements of lead concen-
tration during early development also facili-
tate estimating developmental windows in 
which lead exposure may exert its effects on 
regulatory DMRs. Furthermore, blood lead 
concentrations reflect both short- and longer-
term exposure, including lead mobilized from 
physiological deposits.
To our knowledge, our findings repre-
sent the first attempt in humans to quantify 
associations between early lead exposure and 
DNA methylation alterations in adulthood at 
imprinted loci that are known experimentally 
to result in developmental and neurological 
disorders if perturbed early in development. 
Because lead exposure disproportionately 
affects those in the lower socioeconomic 
strata (Emerson 2012; Rai et al. 2012; 
Wright et al. 2008), our findings, if repli-
cated in larger studies, may offer a potential 
explanation for observed DNA methylation 
differences among socioeconomic strata (Szyf 
2012, 2013).
Conclusions
Preventing lead exposure during vulner-
able developmental windows remains sound 
policy. Nevertheless, effective therapeutic and 
public health strategies will depend on a better 
understanding of mechanisms underpinning 
the associations between lead exposure and the 
genesis of neurodevelopmental disorders and 
other poor health outcomes. Improved under-
standing should also guide policy regarding 
the highest tolerable limits in humans, a 
value currently unknown. Although the 
small sample size limits inference, this study 
provides preliminary evidence for significant 
associations between early lead exposure and 
DNA methylation at the regulatory regions 
of PEG3, H19/IGF2, and PLAGL1/HYMAI. 
Because these changes in the epigenome are 
acquired early, resultant shifts in the regula-
tion of imprinted genes may contribute to 
increased risk of poor health outcomes (Ishida 
and Moore 2013; Murphy and Jirtle 2003). 
It remains unknown whether lead exposure 
previously associated with decreased gray 
matter volume (Cecil et al. 2008) and delin-
quent behavior (Dietrich et al. 2001) reported 
in this study population is mediated in part 
by the epigenetic alterations in imprinted 
gene regulatory elements, but this intriguing 
 possibility needs to be investigated.
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